Kyowa Kirin gets some added love from the FDA, winning their second drug OK in 4 months
This is a good year for Kyowa Kirin.
The company touts itself as a Japanese-based drug group with a global focus, and they got a major assist on that score from the FDA on Wednesday with an approval for their cancer drug mogamulizumab. This OK follows close on the heels of another FDA OK for burosumab, a rare disease drug expected to make a significant mark with their partners at Ultragenyx.
Like burosumab, mogamulizumab was dubbed by regulators as a “breakthrough” therapy deserving VIP treatment. To be sold as Poteligeo, the CCR4 drug is designed to treat two rare forms of non-Hodgkin’s lymphoma: mycosis fungoides and Sézary syndrome.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
